麻豆传媒

Oncology/Hematology >

Hematology

News, opinions and meeting coverage in oncology/hematology.

ASH Offers Early Look at Updated SCD Guidelines

Experts formulated >50 recommendations on sickle cell disease

CAR T-Cell Responses Prove Durable in ALL, DLBCL

Two studies demonstrate long-term control in relapsed/refractory disease

Sneak Peek at Practice-Changing Research From ASH 2018

"Big trials, big results," plus sickle cell disease and CAR T-cell therapies

LMWH Prevails for VTE Prevention in Guideline

ASH unveils first six chapters of comprehensive recommendations

FDA Approves Rituximab Biosimilar for NHL

Indications for front line or beyond, single agent or combination

Deaths from Non-Obesity-Related Cancers Higher in T2D

Even in some obesity-related malignancies, high BMI was inversely tied to cancer death

Sickle Cell in the ED: Old Therapies, New Strategies

With treatments unchanged in decades, docs seek to improve delivery

Levaquin With Chemo Reduces Bacteremia in Pediatric AML/ALL

But no advantage seen among those undergoing transplant

FDA Warns Against Long-Term Zmax Use in Certain Cancer Patients

Heightened risk of relapse, death seen in study of stem cell transplant recipients

Decades Later, Mortality for Childhood Transplant Recipients Remains High

Elevated risk requires closer follow-up care

Second Transplant vs Donor Lymphocyte Infusion in Relapsed AML

Both options viable, benefit more clear in certain groups

How Did Theranos' Holmes Fool So Many Smart People?

WSJ's John Carreyrou on how disgraced entrepreneur nearly got away with it

FLT3-ITD Inhibitor Improves Survival in Relapsed AML

More quizartinib-treated patients went on to stem cell transplant

Lymphoma Risk with JAK Inhibitors for MPNs

Preexisting aberrant B-cell clone implicated

Ditching Chemo Appears Viable in Frontline Follicular Lymphoma

PFS 'nearly identical' at 3 years with novel immunomodulatory combination

Ivosidenib Induces Deep Remissions in IDH1-Mutant AML

On strength of phase I data, drug appears headed for FDA approval

Platelet Stimulator OK'd for Liver Disease Patients with Scheduled Procedures

Avatrombopag (Doptelet) is first drug approved for this indication

CBT Tops Acupuncture for Treating Insomnia in Cancer Survivors

But both methods provide alternative to sleeping pills

Shocker! Is Vioxx Coming Back... as an Orphan Drug?

Milton Packer wonders whether its return represents innovation or opportunism

Make the Diagnosis: What鈥檚 to Blame for his Rash and Paresthesia?

Case Findings: A 52-year-old man who was undergoing chemotherapy for leukemia went to the ED 5 days after receiving cytarabine. He complained of a rapid onset of erythematous lesions on his palms and soles accompanied by tingling and burning sensations. Can you diagnose the patient?

New Clues to CAR T-Cell Failure

Chemo effects, T cell energy sources

Tranexamic Acid Immediately After Vaginal Delivery Cuts Risk of PPH

Higher rates of nausea/vomiting, but not severe adverse events

Gladiator Blood and Liquid Gold: Good for What Ails You?

A new book by Lydia Kang, MD, reviews the most dubious cures in history

Mixed Results with Regimens for Older AML Patients

Positive data with venetoclax, liposomal cytarabine-daunorubicin

Longer PFS in Myeloma with Add-On Daratumumab

Anti-CD38 drug boosts response to VMP regimen

Vince DeVita鈥檚 Oncology Opus

Medicine and music share center stage in storied career

CAR T Cells Drive Outcomes in MM

Studies show promise for precision immunotherapy

ORBIT Score Pinpoints Repeat GI Bleeds with Anticoagulation

Patients rated as high risk show greater rates of rebleeding

MSK Cancer Alliance: Mainly About Medicine

Bi-directional relationship strengthens regional cancer care

Cancer Collaboration Founded by 'Bush 41' Closes Its Doors

All agree C-Change fulfilled its mission

Amyloidosis Treatments Miss the Heart of the Problem

Only modest improvement in end organ function

Bangladesh-Boston Collaborate on ASCT Center

Two dozen patients undergo successful stem cell transplant in Dhaka

Survival Boost With Liposomal Tx in Older AML Patients

Agent may also provide a bridge to successful transplant

Novel Sickle Cell Tx Shows Promise for Pain Crises

Monoclonal antibody tied to lower incidence of adverse events

Keeping Chemo Patients Away From Hospitals

Is 'Come Home' ready for prime time?

Former NCI Chief Niederhuber Shifts Gears

At age 78, still active in research and administration

CML Patients Still Benefit from Transplant

Also at SOHO: Ponatinib proves mettle in pretreated CML

MedPAC Looks at Ways to Adjust Misvalued Services

Commission debates grouping CPT codes into families

Hypomethylating Agents Useful in Low-Risk MDS

Objective responses in a majority of patients

Combo Boosts PFS in Tough-to-Treat Myeloma

Recurrent or relapsed disease susceptible to daratumumab-bortezomib-dexamethasone

鈥�

13